Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression.

about

Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression.

Item

http://www.wikidata.org/entity/Q47352578

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Volasertib Enhances Sensitivit ...... gulation of c-FLIP Expression.

@en

Volasertib Enhances Sensitivit ...... gulation of c-FLIP Expression.

@nl

type

Item

label

Volasertib Enhances Sensitivit ...... gulation of c-FLIP Expression.

@en

Volasertib Enhances Sensitivit ...... gulation of c-FLIP Expression.

@nl

prefLabel

Volasertib Enhances Sensitivit ...... gulation of c-FLIP Expression.

@en

Volasertib Enhances Sensitivit ...... gulation of c-FLIP Expression.

@nl

P1476

Volasertib Enhances Sensitivit ...... gulation of c-FLIP Expression.

@en

P2093

Jong-Wook Park

http://www.w3.org/2001/XMLSchema#string

Kyoung-Jin Min

http://www.w3.org/2001/XMLSchema#string

Mi-Yeon Jeon

http://www.w3.org/2001/XMLSchema#string

Seon Min Woo

http://www.w3.org/2001/XMLSchema#string

Seung Un Seo

http://www.w3.org/2001/XMLSchema#string

Shin Kim

http://www.w3.org/2001/XMLSchema#string

Taeg Kyu Kwon

http://www.w3.org/2001/XMLSchema#string

P2860

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells

Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.

Modulating polo-like kinase 1 as a means for cancer chemoprevention

CYP1B1 Activates Wnt/β-Catenin Signaling through Suppression of Herc5-Mediated ISGylation for Protein Degradation on β-Catenin in HeLa Cells

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

P31

scholarly article

P356

10.3390/IJMS18122568

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29186071

http://www.w3.org/2001/XMLSchema#string

P932

5751171

http://www.w3.org/2001/XMLSchema#string